Ronald Aung-Din, M.D.
Dr. Ronald Aung-Din practices General Neurology & Neuro-Psychiatry in Sarasota, FL. He is board-certified by the American Board of Psychiatry & Neurology and is a member of the American Academy of Neurology.
After obtaining Bachelor’s and Master’s degrees in engineering at Bucknell (Lewisburg, PA) and Cornell (Ithaca, NY) Universities, he worked for a period as a supervising engineer. He then attended Columbia University in New York City for Premedical studies, followed by Medical School at University of Texas Southwestern Medical School, Dallas, TX. Residencies in Neurosurgery were at University of Florida, Gainesville, FL. Other studies included a Medical Student Fellowship in Cardiology at Radcliffe Infirmary, Oxford and Clinical Neurology Fellowship at National Hospital for Nervous Disease, Queen Square, London, UK.
He has participated in over 60 pharmaceutical industry-sponsored clinical trials, functioning as Principal Investigator in drug research studies in MS, epilepsy, pain, Parkinson’s disease, and other neurological diseases. Dr. Aung-Din is also active in treating varied neurological and psychiatric conditions using delivery of CNS-active drugs with Neuro-Direct™ technology, developed by him for which 13 US and foreign patents have been granted; with others pending. Publications using this novel therapy in migraine, Parkinson’s disease, and diabetic neuropathy; in addition to articles on the use of cannabidiol, CBD, and the non-cannabis cannabinoid receptor agonist, caryophyllene, have appeared in Drug Development and Delivery.
Neuro-Direct Technology™ is unique in that therapeutic effect occurs through cutaneous free-nerve endings with direct afferent neural connections to the central nervous system, CNS. As such, the general circulation and blood-brain-barrier are bypassed, with avoidance of usual systemic side effects and drug interactions.AfGin Pharma, LLC was founded by Dr. Aung-Din in 2009 to advance this unique technology and its goal of “Enhanced Neuro-Therapeutics through Direct Effects Topical Technology.”
